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Abstract
Aims/hypothesis Despite inverse associations with insulin
resistance and adiposity, adiponectin has been associated
with both increased and decreased risk of cardiovascular
disease. We examined whether adiponectin is associated
with total and cardiovascular mortality in older adults with
well-characterised body composition.
Methods We analysed data from 3,075 well-functioning
adults aged 69–79 years at baseline. Mortality data were
obtained over 6.6±1.6 years. We used Cox proportional
hazards models adjusting for covariates in stages to
examine the association between adiponectin and total and
cardiovascular mortality.
Results There were 679 deaths, 36% of which were from
cardiovascular disease. Unadjusted levels of adiponectin
were not associated with total or cardiovascular mortality.
However, after adjusting for sex and race, adiponectin was
associated with an increased risk of both total mortality
(hazard ratio 1.26, 95% CI 1.15–1.37, per SD) and
cardiovascular mortality (hazard ratio 1.35, 95% CI 1.17–
1.56, per SD). Further adjustment for study site, smoking,
hypertension, diabetes, prevalent heart disease, HDL-
cholesterol, LDL-cholesterol, renal function, fasting insulin,
triacylglycerol, BMI, visceral fat, thigh intermuscular fat
and thigh muscle area did not attenuate this association.
This association between adiponectin and increased mor-
tality risk did not vary by sex, race, body composition,
diabetes, prevalent cardiovascular disease, smoking or
weight loss.
Conclusions/interpretation Higher levels of adiponectin
were associated with increased risks of total and cardiovas-
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Introduction
Adiponectin has been recognised as a biomarker of insulin
resistance, lower levels being associated with higher BMI,
reduced insulin sensitivity and less favourable lipid profiles
[1]. Adiponectin also inhibits the development of athero-
sclerosis by downregulation of vascular adhesion factors,
inhibition of foam cell formation and smooth muscle
migration [2], and anti-inflammatory effects on macro-
phages [1]. These lines of evidence support the hypothesis
that adiponectin may play a protective role in the
development of cardiovascular disease.
However, human studies have shown inconsistent effects
of adiponectin on cardiovascular disease (CVD) and
mortality, possibly because of differences in sex, race/
ethnicity, age or body composition of study populations. A
meta-analysis concluded that the association between
adiponectin and CVD may not be as strong as previously
considered [3].
We addressed these inconsistencies by analysing pro-
spective data collected from older white and black men and
women enrolled in the Health, Aging, and Body Compo-
sition (Health ABC) Study. We examined whether these
associations were affected by well-characterised measures
of body composition, and whether the associations differed
by sex, race, smoking status, diabetes, prevalent CVD,
body composition, weight loss and use of medications.
Methods
Participants in the Health, Aging, and Body Composition
Study (Health ABC Study) were aged between 69 and
79 years at the baseline visit and were recruited between
April 1997 and June 1998 from a random sample of
Medicare beneficiaries from Pittsburgh (PA, USA) and
Memphis (TN, USA). To be eligible, participants had to
report no difficulty in walking 400 m, climbing ten steps or
performing basic activities of daily living. Individuals
requiring assistive ambulatory devices, those with life-
threatening cancers and those planning to move were
excluded. The study was approved by the institutional
review boards of the University of California, San Francisco,
the University of Pittsburgh and the University of Tennessee.
All study participants provided informed consent.
Participants reported their racial group, age, sex, smok-
ing history and comorbid conditions, including asthma/
chronic obstructive pulmonary disease, cancer, chronic
kidney disease, congestive heart failure, CVD, diabetes,
hypertension and stroke/transient ischaemic attack. Hyper-
tension was defined as the use of an antihypertensive
medication or systolic BP >140 mmHg or diastolic BP
>90 mmHg. Diabetes was defined by self-report, use of
drugs to control diabetes, or fasting plasma glucose
≥6.9 mmol/l or 2 h post-challenge glucose ≥11.0 mmol/l.
Body composition (both regional adiposity and lean mass)
was measured by computed tomography using standardised
protocols as previously reported [4].
Participants underwent venipuncture after an overnight
fast. Total adiponectin levels were assayed in 2002–2003
from frozen serum specimens; adiponectin was measured in
duplicate by RIA (Linco, St Charles, MO, USA) with an
intra-assay coefficient of variation of 1.8–3.6%.
Mortality outcomes were assessed until 31 August 2005.
Deaths were adjudicated by a central committee for
immediate and underlying causes of death using established
criteria, including review of death certificate, all recent
hospital records, and interview with the next of kin.
Cardiovascular mortality was defined as atherosclerotic
cardiovascular disease (definite fatal myocardial infarction,
or definite or possible fatal CHD), stroke, atherosclerotic
disease other than coronary or cerebrovascular, and other
CVD.
Associations of baseline covariates with total and CVD
mortality were assessed using Cox models. We rescaled
body composition measures by their standard deviations
and assessed correlations among the body composition
variables to identify and eliminate collinearity. We used
multivariable Cox proportional hazards models to examine
associations between adiponectin and total mortality and
mortality from CVD. In nested sequences of models using
only those with all covariates (n=2,548), we adjusted for
age, sex, race, site, smoking, hypertension, diabetes, CHD,
LDL-cholesterol and estimated GFR. Then, we adjusted our
models for body composition, including BMI, abdominal
visceral fat, thigh intermuscular fat and thigh muscle area.
Last, models were adjusted for HDL-cholesterol, insulin
and triacylglycerol.
We checked whether sex, race, diabetes, CVD, smoking
status, body composition, weight loss and use of medica-
tions may modify the association between adiponectin and
mortality. Participants taking a medication known to
increase adiponectin (insulin, thiazolidinedione, angioten-
sin receptor blockers, angiotensin-converting enzyme inhib-
itors, beta blockers, and/or statins) were compared with
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those not using any of these medications. We also evaluated
adiponectin’s association with mortality per year and by
tertile of follow-up time.
The proportional hazards assumption was verified by
examining plots of Schoenfeld residuals vs transformed
time and assessing interactions of the all predictors with log
transformed time. We used SAS Version 9.1 (SAS Institute,
Cary, NC, USA) and SPlus Version 6.1 (Insightful, Seattle,
WA, USA).
Results
The average age of the 3,075 participants was 73.6±2.9 years.
There were 679 (22.1%) deaths, of which 247 (36.4%) were
from CVD after a mean 6.6±1.6 years of follow-up. Mean
adiponectin concentration was higher in women than in men
(13.3±7.4 vs 9.5±5.6 μg/ml, p<0.001) and in whites than in
blacks (12.8±7.0 vs 9.5±6.3 μg/ml, p<0.001). Lower
adiponectin levels were associated with higher levels of
BMI, abdominal visceral fat, thigh intermuscular fat and
thigh muscle area. Higher adiponectin concentrations were
associated with older age, female sex and chronic kidney
disease (n=653).
Table 1 shows the association between adiponectin and
total and cardiovascular mortality with sequential adjust-
ment. Unadjusted adiponectin concentration showed a
trend towards increased total mortality risk (HR 1.07,
95% CI 0.98–1.16) and cardiovascular mortality risk (HR
1.14, 95% CI 0.99–1.31). After adjustment for only sex or
race, adiponectin was significantly associated with in-
creased risk of both mortality outcomes and remained
robustly associated with increased risk of total mortality
(HR 1.27, 1.14–1.40, per SD) and CVD mortality (HR
1.38, 1.17–1.64, per SD) in models fully adjusted for
body composition, comorbid diseases and metabolic
factors.
We evaluated subgroups between which adiponectin levels
may be expected to vary (Fig. 1). Those with overweight BMI
had increased risk of CVD mortality (p for interaction 0.03).
The association between adiponectin and mortality did not
vary among those with higher or lower levels of regional
adiposity or lean muscle mass. We examined two weight loss
subgroups: (1) weight loss >5% from baseline during follow-
up vs stable weight or weight gain; and (2) weight loss
between age 50 and the baseline visit. We found no evidence
of interaction between adiponectin and prior or prospective
weight loss for either outcome. Among 882 (35%) partic-
ipants taking one or more of the medications that may affect
adiponectin, concentrations were higher among medication
users than among non-users (12.1±6.9 vs 11.2±6.7 μg/ml,
p<0.001). Medication users had higher risk of total mortality
with increasing adiponectin than non-users (p for interaction,
0.02), but there was no difference according to medication
use for CVD mortality (p for interaction, 0.85). This
increased risk of adiponectin with mortality did not vary
with follow-up time.
Discussion
In a cohort of elderly black and white Americans,
adiponectin was significantly associated with increased risk
of both total and cardiovascular mortality after adjusting
only for sex or race. This association was not diminished
after adjusting for other covariates, including body compo-
sition and other variables associated with the metabolic
syndrome. The association was robust and did not vary
with sex, race, smoking, diabetes, CVD, body composition,
weight loss, medication use or length of follow-up.
Once adjusted for either sex or race, the results of our
study are consistent with other published studies showing
that higher adiponectin levels are associated with increased
cardiovascular mortality and all-cause mortality [5, 6].
Table 1 Association between adiponectin and total and cardiovascular mortality with sequential adjustment for explanatory variables in staged
models
Model Total mortality CVD mortalitya
Unadjusted adiponectin per SDb 1.07 (0.98–1.16) 1.14 (0.99–1.31)
Adiponectin adjusted for age and sex 1.16 (1.06–1.26) 1.23 (1.06–1.42)
Model 1c 1.24 (1.13–1.36) 1.36 (1.18–1.57)
Model 2c 1.22 (1.11–1.35) 1.36 (1.16–1.59)
Model 3c 1.27 (1.14–1.40) 1.38 (1.17–1.64)
Data are HR (95% CI)
a Cardiovascular mortality includes all CHD, all stroke and all CVD deaths combined
b Analysed per SD (6.87 μg/ml) increase in adiponectin
cModel 1 was adjusted for age, sex, race, site, smoking, hypertension, diabetes, prevalent CHD, LDL-cholesterol, estimated GFR (per SD) and
current oral oestrogen use; model 2 was model 1 with adjustment for BMI, abdominal visceral fat, thigh intermuscular fat and thigh muscle area
(all per SD); model 3 was model 2 with adjustment for HDL-cholesterol, insulin and triacylglycerol (all natural log transformed)
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However, our results contradict studies that have reported
that higher adiponectin levels are cardioprotective [7–9].
We expected that differences in body composition would
explain the discrepancy in the literature. While each
measure we examined was associated with adiponectin
and mortality univariately, these body composition meas-
ures did not explain or modify the positive association
between adiponectin and mortality. Another explanation
may be that overweight people surviving to old age may
have characteristics that protect them from adverse effects
of overweight. Weight loss is associated with increased
adiponectin levels, and higher adiponectin levels in the
elderly may be a marker for a catabolic process causing
weight loss. However, participants who lost >5% of body
weight had an increase in their risk of mortality similar to
that of those with stable weight or weight gain. Another
possible explanation is that most studies measure total
adiponectin, not its high molecular weight (HMW) com-
plex. A higher ratio of HMW to total adiponectin was best
correlated with enhanced insulin sensitivity [1] and varies
by age, sex and race. However, a recent study found no
association between HMW adiponectin or the ratio of
HMW/total adiponectin and incident CHD [10]. We are
not aware of any studies that have examined the association
between HMW adiponectin and mortality.
Since the Health ABC Study cohort comprises commu-
nity-dwelling older adults without advanced physical or
cognitive impairment, our findings may not generalise to
younger populations or the frail elderly. Unaccounted
associated factors may influence the association of adipo-
nectin with mortality. We had only one baseline measure of
adiponectin, and this snapshot in time may fail to capture
the complexity of the compensatory mechanisms involved
in regulating adiponectin concentrations prior to death.
In this prospective analysis of elderly black and white
men and women, adiponectin was associated with increased
total and cardiovascular mortality. Body composition,
comorbid diseases, metabolic covariates, weight loss and
medication use did not explain this increased risk of
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Fig. 1 Association between adiponectin (per SD) and total and
cardiovascular mortality by subgroup after adjustment for age, sex,
race, study site, smoking, hypertension, diabetes, prevalent CVD,
LDL-cholesterol, estimated GFR, oestrogen use, BMI, abdominal
visceral fat, thigh intermuscular fat, thigh muscle area, HDL-
cholesterol, insulin and triacylglycerol (without adjustment for the
subgroup variable of interest). The p value for interaction is shown for
each subgroup. Median for abdominal visceral fat was 140.9 cm2 for
men and 119.7 cm2 for women. Median thigh intermuscular fat was
8.45 cm2 for men and 9.32 cm2 for women. Median thigh lean muscle
was 130.5 cm2 for men and 90.7 cm2 for women. ‘Medication user’
refers to any participant taking a medication that increases adiponectin
concentrations: insulin, a thiazolidinedione, an ACE inhibitor, an
angiotensin II receptor blocker, a beta blocker, or a statin medication.
‘Non-user’ refers to those not on any of these medications
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tween the different populations studied may in part explain
previous inconsistencies in the associations of adiponectin
with cardiovascular and total mortality.
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